AVIR insider disclosures
Explore public SEC filings by reporting investor and stock. Filings can appear after the activity they describe. Joint filing lines link to each reporting owner’s profile.
| Reporting investor | Security | Activity | Transaction / period | Filed | Reported amount | Source | Follow |
|---|---|---|---|---|---|---|---|
| Lucidi Bruno Director · Atea Pharmaceuticals, Inc. | AVIR Atea Pharmaceuticals, Inc. | Exercise or conversionFiling detailsSEC transaction code M Stock Option (Right to Buy) · Derivative security · Direct ownership · Reported balance after transaction: 0 · The option is fully vested and exercisable. · All sale transactions reported herein were executed to pay the exercise price of the options and for the Reporting Person's tax planning purposes. | 2026-11-19 | 2026-11-19 | 53,372 shares/units | SEC 4 | Follow |
| Lucidi Bruno Director · Atea Pharmaceuticals, Inc. | AVIR Atea Pharmaceuticals, Inc. | Exercise or conversionFiling detailsSEC transaction code M Stock Option (Right to Buy) · Derivative security · Direct ownership · Reported balance after transaction: 53372 · The option is fully vested and exercisable. · All sale transactions reported herein were executed to pay the exercise price of the options and for the Reporting Person's tax planning purposes. | 2026-11-17 | 2026-11-19 | 21,628 shares/units | SEC 4 | Follow |
| Lucidi Bruno Director · Atea Pharmaceuticals, Inc. | AVIR Atea Pharmaceuticals, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 187990 · SEC code covers open-market or private transactions · The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $3.91 to $3.97. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer full information regarding the number of shares sold at each separate price within the range set forth in this footnote. · All sale transactions reported herein were executed to pay the exercise price of the options and for the Reporting Person's tax planning purposes. | 2026-11-19 | 2026-11-19 | ≈ $89,220.65 22,619 shares/units | SEC 4 | Follow |
| Lucidi Bruno Director · Atea Pharmaceuticals, Inc. | AVIR Atea Pharmaceuticals, Inc. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 210609 · All sale transactions reported herein were executed to pay the exercise price of the options and for the Reporting Person's tax planning purposes. | 2026-11-19 | 2026-11-19 | 53,372 shares/units | SEC 4 | Follow |
| Lucidi Bruno Director · Atea Pharmaceuticals, Inc. | AVIR Atea Pharmaceuticals, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 157237 · SEC code covers open-market or private transactions · The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.00 to $4.10. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer full information regarding the number of shares sold at each separate price within the range set forth in this footnote. · All sale transactions reported herein were executed to pay the exercise price of the options and for the Reporting Person's tax planning purposes. | 2026-11-17 | 2026-11-19 | ≈ $27,189.82 6,741 shares/units | SEC 4 | Follow |
| Lucidi Bruno Director · Atea Pharmaceuticals, Inc. | AVIR Atea Pharmaceuticals, Inc. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 163978 · All sale transactions reported herein were executed to pay the exercise price of the options and for the Reporting Person's tax planning purposes. | 2026-11-17 | 2026-11-19 | 21,628 shares/units | SEC 4 | Follow |
| Polsky Bruce Director · Atea Pharmaceuticals, Inc. | AVIR Atea Pharmaceuticals, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 149830 · SEC code covers open-market or private transactions · The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.00 to $4.04. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer full information regarding the number of shares sold at each separate price within the range set forth in this footnote. · All sale transactions reported herein were executed to pay the exercise price of the options and for the Reporting Person's tax planning purposes. | 2026-11-19 | 2026-11-19 | ≈ $35,298.38 8,750 shares/units | SEC 4 | Follow |
| Polsky Bruce Director · Atea Pharmaceuticals, Inc. | AVIR Atea Pharmaceuticals, Inc. | Exercise or conversionFiling detailsSEC transaction code M Stock Option (Right to Buy) · Derivative security · Direct ownership · Reported balance after transaction: 0 · The option is fully vested and exercisable. · All sale transactions reported herein were executed to pay the exercise price of the options and for the Reporting Person's tax planning purposes. | 2026-11-18 | 2026-11-18 | 18,252 shares/units | SEC 4 | Follow |
| Polsky Bruce Director · Atea Pharmaceuticals, Inc. | AVIR Atea Pharmaceuticals, Inc. | Exercise or conversionFiling detailsSEC transaction code M Stock Option (Right to Buy) · Derivative security · Direct ownership · Reported balance after transaction: 18252 · The option is fully vested and exercisable. · All sale transactions reported herein were executed to pay the exercise price of the options and for the Reporting Person's tax planning purposes. | 2026-11-17 | 2026-11-18 | 8,720 shares/units | SEC 4 | Follow |
| Polsky Bruce Director · Atea Pharmaceuticals, Inc. | AVIR Atea Pharmaceuticals, Inc. | Exercise or conversionFiling detailsSEC transaction code M Stock Option (Right to Buy) · Derivative security · Direct ownership · Reported balance after transaction: 26972 · The option is fully vested and exercisable. · All sale transactions reported herein were executed to pay the exercise price of the options and for the Reporting Person's tax planning purposes. | 2026-11-16 | 2026-11-18 | 48,028 shares/units | SEC 4 | Follow |
| Polsky Bruce Director · Atea Pharmaceuticals, Inc. | AVIR Atea Pharmaceuticals, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 158580 · SEC code covers open-market or private transactions · The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $3.91 to $4.00. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer full information regarding the number of shares sold at each separate price within the range set forth in this footnote. · All sale transactions reported herein were executed to pay the exercise price of the options and for the Reporting Person's tax planning purposes. | 2026-11-18 | 2026-11-18 | ≈ $72,099.05 18,252 shares/units | SEC 4 | Follow |
| Polsky Bruce Director · Atea Pharmaceuticals, Inc. | AVIR Atea Pharmaceuticals, Inc. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 176832 · All sale transactions reported herein were executed to pay the exercise price of the options and for the Reporting Person's tax planning purposes. | 2026-11-18 | 2026-11-18 | 18,252 shares/units | SEC 4 | Follow |
| Polsky Bruce Director · Atea Pharmaceuticals, Inc. | AVIR Atea Pharmaceuticals, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 158580 · SEC code covers open-market or private transactions · The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.00 to $4.10. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer full information regarding the number of shares sold at each separate price within the range set forth in this footnote. · All sale transactions reported herein were executed to pay the exercise price of the options and for the Reporting Person's tax planning purposes. | 2026-11-17 | 2026-11-18 | ≈ $35,155.55 8,720 shares/units | SEC 4 | Follow |
| Polsky Bruce Director · Atea Pharmaceuticals, Inc. | AVIR Atea Pharmaceuticals, Inc. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 167300 · All sale transactions reported herein were executed to pay the exercise price of the options and for the Reporting Person's tax planning purposes. | 2026-11-17 | 2026-11-18 | 8,720 shares/units | SEC 4 | Follow |
| Polsky Bruce Director · Atea Pharmaceuticals, Inc. | AVIR Atea Pharmaceuticals, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 158580 · SEC code covers open-market or private transactions · The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.20 to $4.33. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer full information regarding the number of shares sold at each separate price within the range set forth in this footnote. · All sale transactions reported herein were executed to pay the exercise price of the options and for the Reporting Person's tax planning purposes. | 2026-11-16 | 2026-11-18 | ≈ $60,840.35 14,254 shares/units | SEC 4 | Follow |
| Polsky Bruce Director · Atea Pharmaceuticals, Inc. | AVIR Atea Pharmaceuticals, Inc. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 172834 · All sale transactions reported herein were executed to pay the exercise price of the options and for the Reporting Person's tax planning purposes. | 2026-11-16 | 2026-11-18 | 48,028 shares/units | SEC 4 | Follow |
Form 4 buy and sell codes cover open-market or private transactions. Form 13F shows quarterly reported holdings. Position changes can have causes other than trading. Disclosures are delayed and provided for research.